Skip to main content

Research Repository

Advanced Search

Outputs (35)

Genetic Loss of miR-205 Causes Increased Mammary Gland Development (2023)
Journal Article
Cataldo, A., Cheung, D. G., Hagan, J. P., Fassan, M., Sandhu-Deol, S., Croce, C. M., …Iorio, M. V. (in press). Genetic Loss of miR-205 Causes Increased Mammary Gland Development. Non-Coding RNA, 10(1), Article 4. https://doi.org/10.3390/ncrna10010004

MiRNAs play crucial roles in a broad spectrum of biological processes, both physiological and pathological. Different reports implicate miR-205 in the control of breast stem cell properties. Differential miR-205 expression has been observed in differ... Read More about Genetic Loss of miR-205 Causes Increased Mammary Gland Development.

Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature. (2023)
Journal Article
Taylor, L., Wade, P. K., Johnson, J. E., Aldighieri, M., Morlando, S., Di Leva, G., …Coyle, B. (2023). Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature. Cancers, 15(4), Article 1086. https://doi.org/10.3390/cancers15041086

Therapy resistance represents an unmet challenge in the treatment of medulloblastoma. Accordingly, the identification of targets that mark drug-resistant cell populations, or drive the proliferation of resistant cells, may improve treatment strategie... Read More about Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature..

Correction: MiR-34a/c-Dependent PDGFR-a/ß Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer. (2022)
Journal Article
Garofalo, M., Jeon, Y., Nuovo, G. J., Middleton, J., Secchiero, P., Joshi, P., …Croce, C. M. (2022). Correction: MiR-34a/c-Dependent PDGFR-a/ß Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer. PloS one, e0267628 - ?. https://doi.org/10.1371/journal.pone.0267628

[This corrects the article DOI: 10.1371/journal.pone.0067581.].

UC.183, UC.110, and UC.84 Ultra-Conserved RNAs Are Mutually Exclusive with miR-221 and Are Engaged in the Cell Cycle Circuitry in Breast Cancer Cell Lines. (2021)
Journal Article
Corrà, F., Crudele, F., Baldassari, F., Bianchi, N., Galasso, M., Minotti, L., …Volinia, S. (2021). UC.183, UC.110, and UC.84 Ultra-Conserved RNAs Are Mutually Exclusive with miR-221 and Are Engaged in the Cell Cycle Circuitry in Breast Cancer Cell Lines. Genes, 12(12), Article 1978. https://doi.org/10.3390/genes12121978

In the human genome, there are about 600 ultra-conserved regions (UCRs), long DNA sequences extremely conserved in vertebrates. We performed a large-scale study to quantify transcribed UCR (T-UCR) and miRNA levels in over 6000 cancer and normal tissu... Read More about UC.183, UC.110, and UC.84 Ultra-Conserved RNAs Are Mutually Exclusive with miR-221 and Are Engaged in the Cell Cycle Circuitry in Breast Cancer Cell Lines..

A KRAS-responsive long non-coding RNA controls microRNA processing (2021)
Journal Article
Shi, L., Magee, P., Fassan, M., Sahoo, S., Leong, H. S., Lee, D., …Garofalo, M. (2021). A KRAS-responsive long non-coding RNA controls microRNA processing. Nature communications, 12, Article 2038. https://doi.org/10.1038/s41467-021-22337-3

Wild-type KRAS (KRASWT) amplification has been shown to be a secondary means of KRAS activation in cancer and associated with poor survival. Nevertheless, the precise role of KRASWT overexpression in lung cancer progression is largely unexplored. Her... Read More about A KRAS-responsive long non-coding RNA controls microRNA processing.

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells (2021)
Journal Article
Buzzetti, M., Morlando, S., Solomos, D., Mehmood, A., Cox, A. W., Chiesa, M., …Di Leva, G. (2021). Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells. Scientific reports, 11, Article 5374. https://doi.org/10.1038/s41598-021-84082-3

Medulloblastoma (MB) is the most common aggressive paediatric brain tumour and, despite the recent progress in the treatments of MB patients, there is still an urgent need of complementary or alternative therapeutic options for MB infants. Cyclin Dep... Read More about Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells.

Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition (2020)
Journal Article
Paliouras, A. R., Buzzetti, M., Shi, L., Donaldson, I. J., Magee, P., Sahoo, S., …Garofalo, M. (2020). Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition. EMBO Molecular Medicine, 12(7), Article e11099. https://doi.org/10.15252/emmm.201911099

A subset of lung adenocarcinomas is driven by the EML4-ALK translocation. Even though ALK inhibitors in the clinic lead to excellent initial responses, acquired resistance to these inhibitors due to on-target mutations or parallel pathway alterations... Read More about Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition.

Telomerase inhibition, telomere attrition and proliferation arrest of cancer cells induced by phosphorothioate ASO-NLS conjugates targeting hTERC and siRNAs targeting hTERT (2020)
Journal Article
Diala, I., Shiohama, Y., Fujita, T., Kotake, Y., Demonacos, C., Krstic-Demonacos, M., …Fujii, M. (2020). Telomerase inhibition, telomere attrition and proliferation arrest of cancer cells induced by phosphorothioate ASO-NLS conjugates targeting hTERC and siRNAs targeting hTERT. Nucleosides, Nucleotides and Nucleic Acids, 39(1-3), 407 - 425. https://doi.org/10.1080/15257770.2020.1713357

Telomerase activity has been regarded as a critical step in cellular immortalization and carcinogenesis and because of this, regulation of telomerase represents an attractive target for anti-tumor specific therapeutics. Recently, one avenue of cancer... Read More about Telomerase inhibition, telomere attrition and proliferation arrest of cancer cells induced by phosphorothioate ASO-NLS conjugates targeting hTERC and siRNAs targeting hTERT.